Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I–IIIA operable breast cancer (tumor size ≥ 1.5 cm) were randomized to receive chemotherapy plus trastuzumab and pertuzumab (HP; group A) or HP ± endocrine therapy (group B).
Publication Date 10-1-2025 Journal British Journal of Cancer PubMedCentral® Posted Date 9-1-2025 PubMedCentral® Full Text Version Post-print Published Open-Access yes Recommended Citation Dustin, Derek; Gu, Guowei; Beyer, Amanda R; et al., "Correction: Ron Signalling Promotes Therapeutic Resistance in ESR1 Mutant Breast Cancer" (2025). Faculty, Staff and Students Publications. 7898. https://digitalcommons.library.tmc.edu/baylor_docs/7898 COinS
Abstract Background Oestrogen Receptor 1 (ESR1) mutations are frequently acquired in oestrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who were treated with aromatase inhibitors (AI) in the metastatic setting. Acquired ESR1 mutations are associated with poor prognosis and there is a lack of effective therapies that selectively target these cancers.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
